Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 9189483, 9 pages
http://dx.doi.org/10.1155/2016/9189483
Review Article

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

1Interdisziplinäres Tumorzentrum, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
2Department of Surgery, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
3Krebszentrum Reutlingen, Reutlingen, Germany
4University of Pisa, Pisa, Italy
5Department of Nursing and Health, University of Applied Sciences of the Saarland, Saarbrücken, Germany
6University Cancer Center Leipzig (UCCL), Universitätsklinikum Leipzig, Leipzig, Germany

Received 14 March 2016; Accepted 19 July 2016

Academic Editor: Alessandro Passardi

Copyright © 2016 R.-D. Hofheinz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Cunningham, I. Lang, E. Marcuello et al., “Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 14, no. 11, pp. 1077–1085, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. L. B. Saltz, S. Clarke, E. Diaz-Rubio et al., “Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2013–2019, 2008. View at Publisher · View at Google Scholar
  4. N. C. Tebbutt, K. Wilson, V. J. Gebski et al., “Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3191–3198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Bendell, T. S. Bekaii-Saab, A. L. Cohn et al., “Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study,” Oncologist, vol. 17, no. 12, pp. 1486–1495, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Grothey, M. M. Sugrue, D. M. Purdie et al., “Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE),” Journal of Clinical Oncology, vol. 26, no. 33, pp. 5326–5334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Boehm, J. Folkman, T. Browder, and M. S. O'Reilly, “Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance,” Nature, vol. 390, no. 6658, pp. 404–407, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Klement, P. Huang, B. Mayer et al., “Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts,” Clinical Cancer Research, vol. 8, no. 1, pp. 221–232, 2002. View at Google Scholar · View at Scopus
  9. J. Bennouna, C. Borg, J.-P. Delord et al., “Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study,” Clinical Colorectal Cancer, vol. 11, no. 1, pp. 38–44, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Masi, F. Loupakis, L. Salvatore et al., “Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: updated results of the phase III ‘BEBYP’ trial by the Gruppo Oncologico Nord Ovest (GONO),” Journal of Clinical Oncology, vol. 31, supplement, abstract 3615, 2013. View at Google Scholar
  11. G. Masi, L. Salvatore, L. Boni et al., “Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial,” Annals of Oncology, vol. 26, no. 4, pp. 724–730, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Van Cutsem, J. Tabernero, R. Lakomy et al., “Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3499–3506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Allegra, R. Lakomy, J. Tabernero et al., “Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: a phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen,” Journal of Clinical Oncology, vol. 30, supplement, abstract 3505, 2012, Proceedings of the 2012 ASCO Annual Meeting. View at Google Scholar
  14. A. Grothey, E. Van Cutsem, A. Sobrero et al., “Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial,” The Lancet, vol. 381, no. 9863, pp. 303–312, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Li, S. Qin, R. Xu et al., “Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 16, no. 6, pp. 619–629, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. L. L. Siu, J. D. Shapiro, D. J. Jonker et al., “Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial,” Journal of Clinical Oncology, vol. 31, no. 19, pp. 2477–2484, 2013. View at Publisher · View at Google Scholar
  17. T. Hoehler, T. Decker, C. Schimanski et al., “Final results of the AIO 0307 study: a controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment,” Journal of Clinical Oncology, vol. 31, supplement, abstract 3586, 2013, Proceedings of the 2013 ASCO Annual Meeting. View at Google Scholar
  18. J. Tabernero, T. Yoshino, A. L. Cohn et al., “Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study,” The Lancet Oncology, vol. 16, no. 5, pp. 499–508, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” Journal of Clinical Epidemiology, vol. 62, no. 10, pp. 1006–1012, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Grothey, E. E. Hedrick, R. D. Mass et al., “Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 183–189, 2008. View at Publisher · View at Google Scholar · View at Scopus